Compare Stocks: DXR, PROF, ELMD, and STIM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXR Daxor	$10.76 +2.9%	$10.40	$8.56 ▼ $14.76	$61.07M	0.26	9,950 shs	14,968 shs
ELMD Electromed	$27.07 -1.6%	$38.99	$23.01 ▼ $47.40	$230.15M	0.46	77,109 shs	78,100 shs
PROF Profound Medical	$6.80 -0.1%	$7.08	$3.76 ▼ $8.95	$248.79M	0.72	90,226 shs	323,054 shs
STIM Neuronetics	$3.04 +3.8%	$2.36	$0.80 ▼ $3.71	$223.26M	1.16	1.35 million shs	1.42 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXR Daxor	+4.01%	+3.30%	+5.54%	+9.67%	-5.61%
ELMD Electromed	-1.60%	-4.14%	-36.43%	-28.02%	+1.73%
PROF Profound Medical	-0.15%	-0.29%	-7.36%	+2.26%	+66.67%
STIM Neuronetics	+3.75%	+9.75%	+40.09%	+132.06%	-17.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXR Daxor	$10.76 +2.9%	$10.40	$8.56 ▼ $14.76	$61.07M	0.26	9,950 shs	14,968 shs
ELMD Electromed	$27.07 -1.6%	$38.99	$23.01 ▼ $47.40	$230.15M	0.46	77,109 shs	78,100 shs
PROF Profound Medical	$6.80 -0.1%	$7.08	$3.76 ▼ $8.95	$248.79M	0.72	90,226 shs	323,054 shs
STIM Neuronetics	$3.04 +3.8%	$2.36	$0.80 ▼ $3.71	$223.26M	1.16	1.35 million shs	1.42 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXR Daxor	+4.01%	+3.30%	+5.54%	+9.67%	-5.61%
ELMD Electromed	-1.60%	-4.14%	-36.43%	-28.02%	+1.73%
PROF Profound Medical	-0.15%	-0.29%	-7.36%	+2.26%	+66.67%
STIM Neuronetics	+3.75%	+9.75%	+40.09%	+132.06%	-17.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXR Daxor	2.50	Moderate Buy	N/A	N/A
ELMD Electromed	2.75	Moderate Buy	$43.75	61.62% Upside
PROF Profound Medical	2.67	Moderate Buy	$11.50	69.12% Upside
STIM Neuronetics	2.50	Moderate Buy	$4.50	48.03% Upside

Current Analyst Ratings Breakdown

Latest DXR, PROF, ELMD, and STIM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	STIM Neuronetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.00
8/26/2026	ELMD Electromed	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$50.00
8/26/2026	ELMD Electromed	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $47.00
8/12/2026	PROF Profound Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	STIM Neuronetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $6.00
7/29/2026	PROF Profound Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/27/2026	PROF Profound Medical	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$11.00
7/21/2026	STIM Neuronetics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
7/20/2026	STIM Neuronetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
7/14/2026	PROF Profound Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	ELMD Electromed	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXR Daxor	N/A	N/A	N/A	N/A	N/A	N/A
ELMD Electromed	$73.78M	3.07	$0.65 per share	41.36	$5.10 per share	5.31
PROF Profound Medical	$16.10M	15.43	N/A	N/A	$1.83 per share	3.72
STIM Neuronetics	$149.16M	1.55	N/A	N/A	$0.38 per share	8.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXR Daxor	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELMD Electromed	$5.15M	$1.31	36.09	N/A	N/A	11.34%	15.71%	13.37%	N/A
PROF Profound Medical	-$42.57M	-$0.98	N/A	N/A	N/A	-171.57%	-63.03%	-51.24%	11/12/2026 (Estimated)
STIM Neuronetics	-$39M	-$0.44	N/A	N/A	N/A	-19.62%	-125.11%	-22.15%	11/3/2026 (Estimated)

Latest DXR, PROF, ELMD, and STIM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	STIM Neuronetics	-$0.1230	-$0.05	+$0.0730	-$0.05	$40.17 million	$41.57 million
8/6/2026	Q2 2026	PROF Profound Medical	-$0.22	-$0.26	-$0.04	$0.26	$4.75 million	$2.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXR Daxor	N/A	N/A	N/A	N/A	N/A
ELMD Electromed	N/A	N/A	N/A	N/A	N/A
PROF Profound Medical	N/A	N/A	N/A	N/A	N/A
STIM Neuronetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXR Daxor	N/A	N/A	N/A
ELMD Electromed	N/A	5.10	4.74
PROF Profound Medical	N/A	6.46	5.31
STIM Neuronetics	2.84	1.88	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXR Daxor	1.34%
ELMD Electromed	40.82%
PROF Profound Medical	47.86%
STIM Neuronetics	53.59%

Insider Ownership

Company	Insider Ownership
DXR Daxor	51.50%
ELMD Electromed	10.50%
PROF Profound Medical	1.52%
STIM Neuronetics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXR Daxor	37	5.84 million	2.83 million	Not Optionable
ELMD Electromed	160	8.37 million	7.36 million	Optionable
PROF Profound Medical	150	36.53 million	35.98 million	Optionable
STIM Neuronetics	180	76.20 million	69.80 million	Optionable

DXR, PROF, ELMD, and STIM Headlines

Recent News About These Companies

BTIG Research Reaffirms "Buy" Rating for Neuronetics (NASDAQ:STIM)

September 9 at 8:05 AM | marketbeat.com

NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System

September 8 at 8:32 AM | globenewswire.com

BlackRock Inc. Invests $776,000 in Neuronetics, Inc. $STIM

September 7 at 3:36 AM | marketbeat.com

18,540,488 Shares in Neuronetics, Inc. $STIM Purchased by Madryn Asset Management LP

August 29, 2026 | marketbeat.com

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

August 18, 2026 | finance.yahoo.com

Neuronetics (NASDAQ:STIM) Major Shareholder Acquires 14,000 Shares of Stock

August 18, 2026 | insidertrades.com

Neuronetics (NASDAQ:STIM) Major Shareholder Buys $44,240.00 in Stock

August 17, 2026 | marketbeat.com

Neuronetics, Inc. (STIM) Q2 FY2026 earnings call transcript

August 12, 2026 | finance.yahoo.com

Neuronetics Inc (STIM) (Q2 2026) Earnings Call Highlights: Revenue Growth and Margin Expansion ...

August 12, 2026 | finance.yahoo.com

Neuronetics: Q2 Earnings Snapshot

August 11, 2026 | wtop.comW

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

August 11, 2026 | markets.businessinsider.com

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Neuronetics narrows Q2 loss as Greenbrook growth drives 9% revenue increase

August 11, 2026 | msn.com

BTIG Research Forecasts Strong Price Appreciation for Neuronetics (NASDAQ:STIM) Stock

August 11, 2026 | marketbeat.com

Neuronetics Q2 Earnings Call Highlights

August 11, 2026 | marketbeat.com

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

August 11, 2026 | zacks.com

Neuronetics (NASDAQ:STIM) Announces Earnings Results

August 11, 2026 | marketbeat.com

Neuronetics Reports Second Quarter 2026 Results, Highlights Revenue Growth and Improved Adjusted EBITDA

August 11, 2026 | quiverquant.comQ

Malvern’s Neuronetics reaches deal with shareholder who pushed to break up company

August 5, 2026 | msn.com

Neuronetics and Jorey Chernett Announce Shared Vision

August 3, 2026 | globenewswire.com

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DXR, PROF, ELMD, and STIM Company Descriptions

Daxor NASDAQ:DXR

$10.76 +0.30 (+2.87%)

Closing price 09/9/2026 03:59 PM Eastern

Extended Trading

$10.93 +0.17 (+1.58%)

As of 09/9/2026 07:30 PM Eastern

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Electromed NYSE:ELMD

$27.07 -0.44 (-1.60%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$27.11 +0.04 (+0.15%)

As of 09/9/2026 07:30 PM Eastern

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Profound Medical NASDAQ:PROF

$6.80 -0.01 (-0.15%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$6.80 0.00 (0.00%)

As of 09/9/2026 07:23 PM Eastern

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Neuronetics NASDAQ:STIM

$3.04 +0.11 (+3.75%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$3.07 +0.03 (+1.12%)

As of 09/9/2026 07:58 PM Eastern

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DXR, PROF, ELMD, and STIM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DXR, PROF, ELMD, and STIM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DXR, PROF, ELMD, and STIM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DXR, PROF, ELMD, and STIM Company Descriptions

Daxor NASDAQ:DXR

Electromed NYSE:ELMD

Profound Medical NASDAQ:PROF

Neuronetics NASDAQ:STIM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DXR, PROF, ELMD, and STIM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DXR, PROF, ELMD, and STIM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DXR, PROF, ELMD, and STIM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DXR, PROF, ELMD, and STIM Company Descriptions

Daxor NASDAQ:DXR

Electromed NYSE:ELMD

Profound Medical NASDAQ:PROF

Neuronetics NASDAQ:STIM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools